AFFILIATIONS
1 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
2 Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
3 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
4 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
5 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
6 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
7 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
8 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
9 Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
10 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
11 National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China
ABSTRACT
Background: Patients with mantle cell lymphoma (MCL) harboring TP53 aberrations or blastoid morphology have poor outcomes with conventional chemoimmunotherapy. Whether next-generation Bruton tyrosine kinase inhibitor (BTKi)-based chemoimmunotherapy can overcome this adverse biology remains unclear.
Methods: We conducted a prospective phase II study evaluating frontline zanubrutinib plus bendamustine and rituximab (ZBR) in newly diagnosed biologically high-risk or transplant-ineligible MCL. Patients received six induction cycles of ZBR followed by zanubrutinib maintenance. Targeted sequencing, longitudinal circulating tumor DNA (ctDNA), and RNA sequencing were integrated to characterize molecular response and resistance.
Results: Twenty-three patients were enrolled, including 52.2% with TP53 aberrations and 26.1% with blastoid morphology. Patients harboring TP53 aberrations achieved progression-free survival comparable to TP53 wild-type patients, whereas blastoid morphology remained associated with inferior outcomes. After a median follow-up of 28.6 months, the median PFS had not been reached. The ORR and CR rates were 91.3% and 87.0%, respectively, with estimated 2-year PFS and OS rates of 78.3% and 87.0%, respectively. Longitudinal ctDNA demonstrated rapid molecular clearance in responders, whereas persistent or rebounding ctDNA preceded disease progression and was accompanied by re-emergence of TP53-mutant clones. Resistant tumors were enriched for KMT2D mutations, activation of cell-cycle pathways, and reduced CD8+ T-cell infiltration.
Conclusions: Frontline ZBR demonstrated promising activity in biologically high-risk MCL and may attenuate the adverse prognostic impact of TP53 aberrations. Integrated molecular profiling identified biomarkers of response and relapse, providing biological insights into mechanisms of therapeutic resistance. This trial was registered at www.ClinicalTrials.gov as #NCT06136351.
DISCLOSURES
Yaohui Huang Jr: No relevant conflicts of interest to declare.